



BIOTECHNOLOGY FROM IDEA TO MARKET

“ Whether a student or a professional engaged in biotechnology, whether in academia or the private sector, no single individual can be expert in all aspects of this industry. For anyone who wants to excel in biotechnology, this book presents a wonderful guide. ”

Phillip A. Sharp, Ph.D., Nobel Laureate in Physiology or Medicine 1993
Co-founder Biogen (now Biogen Idec) and co-founder of Alnylam
Pharmaceuticals



Editors:

Fred Mermelstein, Richard Prince and Carl Novina

Over 1,000 pages, this text discusses topics such as:

- ◆ First Principles of R&D
- ◆ Translation of Science into Products
- ◆ Founding a Biotechnology Company
- ◆ Composing a Business Plan
- ◆ Financing Biotechnology Start-ups
- ◆ Performing Clinical Trials and Development
- ◆ Safeguarding Clinical Development
- ◆ A Primer on Getting Products Approved
- ◆ Designing and Building a Facility
- ◆ Manufacturing
- ◆ QC testing
- ◆ Licensing and Many Other Legal Considerations
- ◆ Understanding Drug Pricing and Reimbursement
- ◆ Regulatory Considerations

A complete Table of Contents and authors can be found on the following 2 pages.

“
Each chapter,
written by
experienced subject
matter experts, is
equivalent to hiring
consultants to
advise from idea to
market. This text is
an invaluable guide
and reference.”

Fred Mermelstein, PhD
Entrepreneur-in-Residence
Dana-Farber Cancer Institute
Lecturer, Dept. of Neurobiology
Harvard Medical School
Founding Partner
Ascentia Asset Management, Inc.




Richard Prince, PhD
Chief Executive Officer
Now Biopharma, LLC
President
Pollination Ventures Management, LLC



Carl D. Novina, MD, PhD
Associate Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Associate Member
Broad Institute of Harvard and MIT



CONTENTS



Foreword
Phillip A. Sharp

Introduction
Fred Mermelstein, Richard Prince and Carl Novina

SECTION 1 DUE DILIGENCE


1. FIRST PRINCIPLES OF R&D –THE ROLE OF DUE DILIGENCE
Fred Mermelstein
2. TRANSLATIONAL RESEARCH IN ACADEMIA – MOVING TOWARDS THE D SIDE OF R&D
Carl D. Novina
3. THE TARGET PRODUCT PROFILE SHEET – AN INVALUABLE TOOL IN R&D PLANNING
Shani C. Missner and Matthew R.Weinberg
4. FOUNDING A BIOTECHNOLOGY COMPANY
Alan Crane
5. MEDICAL DEVICES – FROM IDEA TO MARKET
John Butziger and Laurie Bourgeois
6. HOW TO COMPOSE A BUSINESS PLAN
Douglas A. Hamilton

SECTION 2 FINANCING

7. CORPORATE COMMUNICATIONS – EXECUTIVE SUMMARIES AND PITCH DECKS
Dian Griesel
8. FINANCING BIOTECHNOLOGY START-UPS –THE ROLE OF THE LICENSED BROKER DEALER
Jeff Eliot Margolis
9. INDUSTRY PARTNERSHIPS AND LIQUIDITY EVENTS – ENGAGING WITH BIG PHARMA
David R. Boyko

SECTION 3 OPERATIONALIZATION

10. REGULATORY AFFAIRS' ROLE IN PRODUCT DEVELOPMENT
David L. Rosen
11. CLINICAL TESTING OF BIOSIMILARS
Sarfaraz K. Niazi





12. SAFEGUARDING CLINICAL DEVELOPMENT – STRATEGIC AND QUALITY CONSIDERATIONS

Richard Prince

13. PERFORMING CLINICAL TRIALS – THE ROLE OF CLINICAL OPERATIONS

Cassandra Erato and Angela Bartkus

14. DESIGNING AND BUILDING A BIOTECHNOLOGY FACILITY

Kim Nelson

15. MANUFACTURING BIOPHARMACEUTICALS – FROM START-UP TO COMMERCIALIZATION

Joseph Waggett and Laura Grayson Roselli

16. QUALITY CONTROL TESTING THROUGHOUT THE PRODUCT DEVELOPMENT LIFECYCLE

Daniel Prince, Martell Winters and Richard Prince

SECTION 4 LEGAL

17. FORMING THE ENTERPRISE AND RAISING CAPITAL

Travis L. Gering

18. ESTABLISHING EFFECTIVE INTELLECTUAL PROPERTY PROTECTION

Christine Willgoos, John P. Dillon and Jonathan S. Caplan

19. LICENSING TECHNOLOGY FROM ACADEMIA AND GOVERNMENT

Lita Nelsen

SECTION 5 COMMERCIALIZATION

20. UNDERSTANDING DRUG PRICING AND REIMBURSEMENT

Joshua P. Cohen

21. GUIDANCE TO PHARMACEUTICAL PRODUCT LAUNCH TIMELINES AND POST MARKET ORGANIZATIONAL EXPANSION

Charles Bell, Suzanne LoGalbo and Elise Fellner Roth

22. PORTFOLIO MANAGEMENT OF CORPORATE ASSETS

Douglas A. Hamilton

GLOSSARY

INDEX

